The use of an intensified form of radiotherapy in patients with locally advanced head and neck cancers can improve overall survival rates compared with standard radiation therapy. This is the conclusion drawn from results from a large study presented at the 2013 European Cancer Congress (ECC2013).…Continue
Added by Editorial Team on September 28, 2013 at 3:00pm — No Comments
A highly targeted cancer radiation therapy called stereotactic body radiotherapy or SBRT may offer a safe and effective treatment option for elderly pancreatic cancer patients unable to undergo surgery or combined chemotherapy and radiation therapy, according to researchers at Henry Ford Hospital in Detroit.
A stereotactic radiation treatment is a method of giving radiation that can be highly targeted to the tumor,…Continue
Added by Editorial Team on September 24, 2013 at 8:30am — No Comments
Results of a study presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting held in Atlanta, September 22-25, 2013 shows that Sulfasalazine (Azulfidine®, Pfizer), a drug commonly prescribed to reduce diarrhea in patients with rectal bleeding and abdominal pain in patients with ulcerative colitis, a condition in which the bowel is inflamed, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area. The study…Continue
Added by Peter Hofland, PhD on September 24, 2013 at 6:00am — No Comments
Results of the Phase II clinical trial of patients with brain metastases presented today at the American Society for Radiation Oncology (ASTRO) annual meeting shows the benefits of protecting the stem cells that reside in and around the hippocampus. The hippocampus is a C-shaped area in the temporal lobe on both sides of the brain associated with the ability to form and store memories. Protecting the hippocampus substantially reduces the rate of cancer patients' memory loss during…Continue
Added by Editorial Team on September 23, 2013 at 1:00pm — No Comments
Radiation is a common tool in the treatment of brain tumors and may induces neurological side effect. Scientists today, have long believed that healthy brain cells, once damaged by radiation designed to kill brain tumors, cannot regenerate. But new research in mice, conducted by scientists at Johns Hopkins suggests that neural stem/precursor cells (NSCs), the body's source of new brain cells, are resistant to radiation. The researchers found that these neural stem cells can be roused…Continue
Added by Editorial Team on August 12, 2013 at 3:30pm — No Comments
In a recently published study, neurosurgeons found that a new MRI-guided laser treatment used for the first time in a human study called NeuroBlate™ Thermal Therapy System (formerly known as AutoLITT™) a from of Laser Interstitial Thermal Therapy or LITT, offers them a new, safe and minimally invasive procedure for treating recurrent glioblastoma (GBM), a malignant type of brain tumor.
In the article, published in the April 5, 2013 online edition of the…Continue
Added by Peter Hofland, PhD on April 5, 2013 at 8:30am — No Comments
A first long-term study of the full-population health impacts of the closure of nuclear reactor in the United States found 4,319 fewer cancers over 20 years, with declines in cancer incidence in 28 of 31 categories (14 of them statistically significant), including notable drops in cancer for women, Hispanics and children.
In their article, published Biomedicine International, an open access peer-reviewed…Continue
Added by Peter Hofland, PhD on March 28, 2013 at 10:30am — No Comments
A promising new approach to treating solid tumors with radiation was highly efficacious and minimally toxic to healthy tissue in a mouse model of cancer, according to data published in November 15, 2012 issue of Cancer Research, a journal of the American Association for Cancer Research.
Patients with solid tumors, including prostate cancer, are often treated using a clinical technique called brachytherapy. Brachytherapy involves the surgical implantation of radioactive…Continue
Added by Peter Hofland, PhD on November 15, 2012 at 11:30am — No Comments
The Death of his first wife makes improving the Quality of Life (QoL) for patients with a brain tumor very personal for Mike Robbins, associate director of the Thomas K. Hearn Jr. Brain Tumor Research Center at Wake Forest Baptist Medical Center. Robbins knows all too well that the likely outcome when patients are diagnosed with brain tumors that are "high grade" may not always be positive.
Added by Peter Hofland, PhD on June 26, 2012 at 11:00am — No Comments
Earlier today, Bert Vorstman, M.D., a Florida urologist with nearly 30 years expertise in prostate cancer diagnosis and treatment, launched a series of exclusive medical reports detailing information and misinformation about prostate cancer screening and treatment options, including myths and marketing related information behind.
Vorstman releases his…
Added by Peter Hofland, PhD on June 26, 2012 at 10:30am — No Comments
Research published in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning. Scientists in the multi-institutional study – posted online by the journal on June 24, 2012 – say their findings open the potential for new treatments against radiation toxicity during cancer treatment or environmental…Continue
Added by Peter Hofland, PhD on June 24, 2012 at 10:00am — No Comments
A study finds that female survivors of childhood cancer treated with radiation to the chest had a high risk of developing breast cancer at a young age, comparable to that of BRCA1/2 mutation carriers. The findings also suggest that more survivors may be affected than previously thought. The results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Added by Peter Hofland, PhD on June 5, 2012 at 6:30pm — No Comments
The first cohort in a U.S. multi-center Phase 1b dose-escalation trial of a novel cancer-targeted molecular radiotherapeutic compound (I-131-CLR1404; Novelos Therapeutics, Inc.), in cancer patients with advanced solid tumors has been successfully completed. The first two-patient cohort was successfully dosed with approximately 20 mCi of I-131-CLR1404, triggering enrollment into the second cohort at approximately 40…Continue
Added by Peter Hofland, PhD on May 15, 2012 at 5:30am — No Comments
According to a study published in the American Journal of Roentgenology (AJR) in January 2012, Molecular Breast Imaging (MBI), also known as Breast-Specific Gamma Imaging or BSGI, can detect cancers missed by the two most common breast imaging studies, mammography and ultrasound. To clearly differentiate between benign from malignant tissue after mammography, phycians perform BSGI/MBI. In this procedure a patient receives a…Continue
Added by Peter Hofland, PhD on February 14, 2012 at 6:00am — No Comments
A large comparative effectiveness study presented at the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Ca, USA, shows that men with localized prostate cancer who are treated with Intensity Modulated Radiation Therapy or IMRT are less likely to experience cancer recurrences or significant side effects from treatment than those who receive conventional conformal radiation therapy…Continue
Added by Peter Hofland, PhD on February 2, 2012 at 3:00pm — No Comments
A Danish national fast track system for cancer patients reduced the waiting time between a patient’s initial meeting with a health care provider and their first treatment by four weeks when comparing 2010 to 2002, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.
Denmark’s health care system is state run. Health care services are funded by taxes with no…
Added by Peter Hofland, PhD on January 26, 2012 at 2:30pm — No Comments
Added by Peter Hofland, PhD on January 26, 2012 at 11:30am — No Comments
The U.S. Food and Drug Administration (FDA) has invited Amgen to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for denosumab (XGEVA®) to treat men with castration-resistant…Continue
Added by Peter Hofland, PhD on December 29, 2011 at 3:30pm — No Comments
A large, retrospective study published in the Journal of Clinical Oncology, a tri-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), shows that children of childhood cancer survivors who received prior treatment involving radiation to testes or ovaries and/or chemotherapy with alkylating agents do not have an increased risk for birth…Continue
Added by Peter Hofland, PhD on December 12, 2011 at 6:00pm — No Comments
Doses of a neurotransmitter might offer a way to boost the effectiveness of anticancer drugs and radiation therapy, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Using animal models of human breast and prostate cancers, the researchers found that injections of the…
Added by Peter Hofland, PhD on December 4, 2011 at 5:30pm — No Comments